Authors: McKenna, F Weaver, A Fiechtner, JJ Bello, AE Fort, JG

Citation: F. Mckenna et al., COX-2 specific inhibitors in the management of osteoarthritis of the knee:A placebo-controlled, randomized, double-blind study, JCR-J CLIN, 7(3), 2001, pp. 151-159

Authors: Zhao, SZ Dedhiya, SD Bocanegra, TS Fort, JG Kuss, ME Rush, SM

Citation: Sz. Zhao et al., Health-related quality-of-life effects of oxaprozin and nabumetone in patients with osteoarthritis of the knee, CLIN THER, 21(1), 1999, pp. 205-217

Authors: Simon, LS Zhao, SZ Arguelles, LM Lefkowith, JB Dedhiya, SD Fort, JG Johnson, KE

Citation: Ls. Simon et al., Economic and gastrointestinal safety comparisons of etodolac, nabumetone, and oxaprozin from insurance claims data from patients with arthritis, CLIN THER, 20(6), 1998, pp. 1218-1235